[
{
"old_id":"1",
"old_nametree":"Authors and legal information",
"old_numtree":"1.0.0.0",
"old_htmlpage":"ENAS5266_1.0.0.0",
"new_id":"1",
"new_nametree":"Authors and legal information",
"new_numtree":"1.0.0.0",
"new_htmlpage":"ENAS5266_1.0.0.0"
},
{
"old_id":"2",
"old_nametree":"CV eval. before anticancer treatment",
"old_numtree":"2.0.0.0",
"old_htmlpage":"ENAS5266_2.0.0.0",
"new_id":"2",
"new_nametree":"CV eval. before anticancer treatment",
"new_numtree":"2.0.0.0",
"new_htmlpage":"ENAS5266_2.0.0.0"
},
{
"old_id":"3",
"old_nametree":"Left ventricular dysfunction (LVD)",
"old_numtree":"3.0.0.0",
"old_htmlpage":"null",
"new_id":"3",
"new_nametree":"Left ventricular dysfunction (LVD)",
"new_numtree":"3.0.0.0",
"new_htmlpage":"null"
},
{
"old_id":"4",
"old_nametree":"Overview",
"old_numtree":"3.1.0.0",
"old_htmlpage":"ENAS5266_3.1.0.0",
"new_id":"4",
"new_nametree":"Overview",
"new_numtree":"3.1.0.0",
"new_htmlpage":"ENAS5266_3.1.0.0"
},
{
"old_id":"5",
"old_nametree":"Anthracyclines and cardiotoxicity",
"old_numtree":"3.2.0.0",
"old_htmlpage":"null",
"new_id":"5",
"new_nametree":"Anthracyclines and cardiotoxicity",
"new_numtree":"3.2.0.0",
"new_htmlpage":"null"
},
{
"old_id":"6",
"old_nametree":"Overview",
"old_numtree":"3.2.1.0",
"old_htmlpage":"ENAS5266_3.2.1.0",
"new_id":"6",
"new_nametree":"Overview",
"new_numtree":"3.2.1.0",
"new_htmlpage":"ENAS5266_3.2.1.0"
},
{
"old_id":"7",
"old_nametree":"Mgmt. of cardiotoxicity",
"old_numtree":"3.2.2.0",
"old_htmlpage":"ENAS5266_3.2.2.0",
"new_id":"7",
"new_nametree":"Mgmt. of cardiotoxicity",
"new_numtree":"3.2.2.0",
"new_htmlpage":"ENAS5266_3.2.2.0"
},
{
"old_id":"8",
"old_nametree":"Monoclonal antibodies and targeted agents",
"old_numtree":"3.3.0.0",
"old_htmlpage":"ENAS5266_3.3.0.0",
"new_id":"8",
"new_nametree":"Monoclonal antibodies and targeted agents",
"new_numtree":"3.3.0.0",
"new_htmlpage":"ENAS5266_3.3.0.0"
},
{
"old_id":"9",
"old_nametree":"Trastuzumab cardiotox. adjuvant trials",
"old_numtree":"3.4.0.0",
"old_htmlpage":"null",
"new_id":"9",
"new_nametree":"Trastuzumab cardiotox. adjuvant trials",
"new_numtree":"3.4.0.0",
"new_htmlpage":"null"
},
{
"old_id":"10",
"old_nametree":"Overview",
"old_numtree":"3.4.1.0",
"old_htmlpage":"ENAS5266_3.4.1.0",
"new_id":"10",
"new_nametree":"Overview",
"new_numtree":"3.4.1.0",
"new_htmlpage":"ENAS5266_3.4.1.0"
},
{
"old_id":"11",
"old_nametree":"Mgmt. of trastuzumab cardiotoxicity",
"old_numtree":"3.4.2.0",
"old_htmlpage":"ENAS5266_3.4.2.0",
"new_id":"11",
"new_nametree":"Mgmt. of trastuzumab cardiotoxicity",
"new_numtree":"3.4.2.0",
"new_htmlpage":"ENAS5266_3.4.2.0"
},
{
"old_id":"12",
"old_nametree":"LVEF: Cont./discont. of Trastuzumab",
"old_numtree":"3.4.3.0",
"old_htmlpage":"ENAS5266_3.4.3.0",
"new_id":"12",
"new_nametree":"LVEF: Cont./discont. of Trastuzumab",
"new_numtree":"3.4.3.0",
"new_htmlpage":"ENAS5266_3.4.3.0"
},
{
"old_id":"13",
"old_nametree":"Cardiac ischaemia",
"old_numtree":"4.0.0.0",
"old_htmlpage":"ENAS5266_4.0.0.0",
"new_id":"13",
"new_nametree":"Cardiac ischaemia",
"new_numtree":"4.0.0.0",
"new_htmlpage":"ENAS5266_4.0.0.0"
},
{
"old_id":"14",
"old_nametree":"Hypertension",
"old_numtree":"5.0.0.0",
"old_htmlpage":"ENAS5266_5.0.0.0",
"new_id":"14",
"new_nametree":"Hypertension",
"new_numtree":"5.0.0.0",
"new_htmlpage":"ENAS5266_5.0.0.0"
},
{
"old_id":"15",
"old_nametree":"QT prolongation",
"old_numtree":"6.0.0.0",
"old_htmlpage":"ENAS5266_6.0.0.0",
"new_id":"15",
"new_nametree":"QT prolongation",
"new_numtree":"6.0.0.0",
"new_htmlpage":"ENAS5266_6.0.0.0"
},
{
"old_id":"16",
"old_nametree":"CV monitoring during & after anticancer Tx",
"old_numtree":"7.0.0.0",
"old_htmlpage":"ENAS5266_7.0.0.0",
"new_id":"16",
"new_nametree":"CV monitoring during & after anticancer Tx",
"new_numtree":"7.0.0.0",
"new_htmlpage":"ENAS5266_7.0.0.0"
},
{
"old_id":"17",
"old_nametree":"Tx of LVD induced by anticancer treatment",
"old_numtree":"8.0.0.0",
"old_htmlpage":"ENAS5266_8.0.0.0",
"new_id":"17",
"new_nametree":"Tx of LVD induced by anticancer treatment",
"new_numtree":"8.0.0.0",
"new_htmlpage":"ENAS5266_8.0.0.0"
},
{
"old_id":"18",
"old_nametree":"Cardiac toxicity induced by RT",
"old_numtree":"9.0.0.0",
"old_htmlpage":"null",
"new_id":"18",
"new_nametree":"Cardiac toxicity induced by RT",
"new_numtree":"9.0.0.0",
"new_htmlpage":"null"
},
{
"old_id":"19",
"old_nametree":"Overview",
"old_numtree":"9.1.0.0",
"old_htmlpage":"ENAS5266_9.1.0.0",
"new_id":"19",
"new_nametree":"Overview",
"new_numtree":"9.1.0.0",
"new_htmlpage":"ENAS5266_9.1.0.0"
},
{
"old_id":"20",
"old_nametree":"Recomm. to reduce cardiac toxicity by RT",
"old_numtree":"9.2.0.0",
"old_htmlpage":"ENAS5266_9.2.0.0",
"new_id":"20",
"new_nametree":"Recomm. to reduce cardiac toxicity by RT",
"new_numtree":"9.2.0.0",
"new_htmlpage":"ENAS5266_9.2.0.0"
},
{
"old_id":"21",
"old_nametree":"Tx of radiotherapy-related cardiac compli.",
"old_numtree":"9.3.0.0",
"old_htmlpage":"ENAS5266_9.3.0.0",
"new_id":"21",
"new_nametree":"Tx of radiotherapy-related cardiac compli.",
"new_numtree":"9.3.0.0",
"new_htmlpage":"ENAS5266_9.3.0.0"
},
{
"old_id":"22",
"old_nametree":"Monitoring of cardiac func. after chest RT",
"old_numtree":"9.4.0.0",
"old_htmlpage":"ENAS5266_9.4.0.0",
"new_id":"22",
"new_nametree":"Monitoring of cardiac func. after chest RT",
"new_numtree":"9.4.0.0",
"new_htmlpage":"ENAS5266_9.4.0.0"
},
{
"old_id":"23",
"old_nametree":"Summary of recommendations",
"old_numtree":"10.0.0.0",
"old_htmlpage":"null",
"new_id":"23",
"new_nametree":"Summary of recommendations",
"new_numtree":"10.0.0.0",
"new_htmlpage":"null"
},
{
"old_id":"24",
"old_nametree":"CV eval. before anticancer treatment",
"old_numtree":"10.1.0.0",
"old_htmlpage":"ENAS5266_10.1.0.0",
"new_id":"24",
"new_nametree":"CV eval. before anticancer treatment",
"new_numtree":"10.1.0.0",
"new_htmlpage":"ENAS5266_10.1.0.0"
},
{
"old_id":"25",
"old_nametree":"Left ventricular dysfunction (LVD)",
"old_numtree":"10.2.0.0",
"old_htmlpage":"null",
"new_id":"25",
"new_nametree":"Left ventricular dysfunction (LVD)",
"new_numtree":"10.2.0.0",
"new_htmlpage":"null"
},
{
"old_id":"26",
"old_nametree":"Overview",
"old_numtree":"10.2.1.0",
"old_htmlpage":"ENAS5266_10.2.1.0",
"new_id":"26",
"new_nametree":"Overview",
"new_numtree":"10.2.1.0",
"new_htmlpage":"ENAS5266_10.2.1.0"
},
{
"old_id":"27",
"old_nametree":"Anthracyclines and cardiotoxicity",
"old_numtree":"10.2.2.0",
"old_htmlpage":"ENAS5266_10.2.2.0",
"new_id":"27",
"new_nametree":"Anthracyclines and cardiotoxicity",
"new_numtree":"10.2.2.0",
"new_htmlpage":"ENAS5266_10.2.2.0"
},
{
"old_id":"28",
"old_nametree":"Monoclonal antibodies and targeted agents",
"old_numtree":"10.2.3.0",
"old_htmlpage":"ENAS5266_10.2.3.0",
"new_id":"28",
"new_nametree":"Monoclonal antibodies and targeted agents",
"new_numtree":"10.2.3.0",
"new_htmlpage":"ENAS5266_10.2.3.0"
},
{
"old_id":"29",
"old_nametree":"Mgmt. of trastuzumab cardiotoxicity",
"old_numtree":"10.2.4.0",
"old_htmlpage":"ENAS5266_10.2.4.0",
"new_id":"29",
"new_nametree":"Mgmt. of trastuzumab cardiotoxicity",
"new_numtree":"10.2.4.0",
"new_htmlpage":"ENAS5266_10.2.4.0"
},
{
"old_id":"30",
"old_nametree":"Cardiac ischaemia",
"old_numtree":"10.3.0.0",
"old_htmlpage":"ENAS5266_10.3.0.0",
"new_id":"30",
"new_nametree":"Cardiac ischaemia",
"new_numtree":"10.3.0.0",
"new_htmlpage":"ENAS5266_10.3.0.0"
},
{
"old_id":"31",
"old_nametree":"Hypertension",
"old_numtree":"10.4.0.0",
"old_htmlpage":"ENAS5266_10.4.0.0",
"new_id":"31",
"new_nametree":"Hypertension",
"new_numtree":"10.4.0.0",
"new_htmlpage":"ENAS5266_10.4.0.0"
},
{
"old_id":"32",
"old_nametree":"QT prolongation",
"old_numtree":"10.5.0.0",
"old_htmlpage":"ENAS5266_10.5.0.0",
"new_id":"32",
"new_nametree":"QT prolongation",
"new_numtree":"10.5.0.0",
"new_htmlpage":"ENAS5266_10.5.0.0"
},
{
"old_id":"33",
"old_nametree":"CV monitoring during & after anticancer Tx",
"old_numtree":"10.6.0.0",
"old_htmlpage":"ENAS5266_10.6.0.0",
"new_id":"33",
"new_nametree":"CV monitoring during & after anticancer Tx",
"new_numtree":"10.6.0.0",
"new_htmlpage":"ENAS5266_10.6.0.0"
},
{
"old_id":"34",
"old_nametree":"Tx of LVD induced by anticancer treatment",
"old_numtree":"10.7.0.0",
"old_htmlpage":"ENAS5266_10.7.0.0",
"new_id":"34",
"new_nametree":"Tx of LVD induced by anticancer treatment",
"new_numtree":"10.7.0.0",
"new_htmlpage":"ENAS5266_10.7.0.0"
},
{
"old_id":"35",
"old_nametree":"Cardiac toxicity induced by RT",
"old_numtree":"10.8.0.0",
"old_htmlpage":"null",
"new_id":"35",
"new_nametree":"Cardiac toxicity induced by RT",
"new_numtree":"10.8.0.0",
"new_htmlpage":"null"
},
{
"old_id":"36",
"old_nametree":"Overview",
"old_numtree":"10.8.1.0",
"old_htmlpage":"ENAS5266_10.8.1.0",
"new_id":"36",
"new_nametree":"Overview",
"new_numtree":"10.8.1.0",
"new_htmlpage":"ENAS5266_10.8.1.0"
},
{
"old_id":"37",
"old_nametree":"Recomm. to reduce cardiac toxicity in RT",
"old_numtree":"10.8.2.0",
"old_htmlpage":"ENAS5266_10.8.2.0",
"new_id":"37",
"new_nametree":"Recomm. to reduce cardiac toxicity in RT",
"new_numtree":"10.8.2.0",
"new_htmlpage":"ENAS5266_10.8.2.0"
},
{
"old_id":"38",
"old_nametree":"Monitoring of cardiac func. after chest RT",
"old_numtree":"10.8.3.0",
"old_htmlpage":"ENAS5266_10.8.3.0",
"new_id":"38",
"new_nametree":"Monitoring of cardiac func. after chest RT",
"new_numtree":"10.8.3.0",
"new_htmlpage":"ENAS5266_10.8.3.0"
},
{
"old_id":"39",
"old_nametree":"Glossary",
"old_numtree":"11.0.0.0",
"old_htmlpage":"ENAS5266_11.0.0.0",
"new_id":"39",
"new_nametree":"Glossary",
"new_numtree":"11.0.0.0",
"new_htmlpage":"ENAS5266_11.0.0.0"
}
]